Reduced striatal tyrosine hydroxylase in incidental Lewy body disease
- PMID: 17985144
- PMCID: PMC2724592
- DOI: 10.1007/s00401-007-0313-7
Reduced striatal tyrosine hydroxylase in incidental Lewy body disease
Abstract
Incidental Lewy body disease (ILBD) is the term used when Lewy bodies are found in the nervous system of subjects without clinically documented parkinsonism or dementia. The prevalence of ILBD in the elderly population has been estimated at between 3.8 and 30%, depending on subject age and anatomical site of sampling. It has been speculated that ILBD represents the preclinical stage of Parkinson's disease (PD) and/or dementia with Lewy bodies (DLB). Studies of ILBD could potentially identify early diagnostic signs of these disorders. At present, however, it is impossible to know whether ILBD is a precursor to PD or DLB or is just a benign finding of normal aging. We hypothesized that, if ILBD represents an early stage of PD or DLB, it should be associated with depletion of striatal dopaminergic markers. Eleven subjects with ILBD and 27 control subjects were studied. The ILBD subjects ranged in age from 74 to 96 years (mean 86.5) while the control subjects' age ranged from 75 to 102 years (mean 86.7). Controls and subjects did not differ in terms of age, postmortem interval, gender distribution, medical history conditions, brain weight, neuritic plaque density or Braak neurofibrillary stage. Quantitative ELISA measurement of striatal tyrosine hydroxylase (TH), the principal enzyme for dopamine synthesis, showed a 49.8% (P = 0.01) reduction in ILBD cases, as compared with control cases. The finding suggests that ILBD is not a benign condition but is likely a precursor to PD and/or DLB.
Figures


Similar articles
-
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.Acta Neuropathol. 2008 Apr;115(4):437-44. doi: 10.1007/s00401-008-0345-7. Epub 2008 Feb 9. Acta Neuropathol. 2008. PMID: 18264713
-
Incidental Lewy body disease and preclinical Parkinson disease.Arch Neurol. 2008 Aug;65(8):1074-80. doi: 10.1001/archneur.65.8.1074. Arch Neurol. 2008. PMID: 18695057
-
Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases.Acta Neuropathol. 2024 Apr 6;147(1):67. doi: 10.1007/s00401-024-02707-z. Acta Neuropathol. 2024. PMID: 38581586 Free PMC article.
-
[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].Rinsho Shinkeigaku. 2008 Jan;48(1):11-24. doi: 10.5692/clinicalneurol.48.11. Rinsho Shinkeigaku. 2008. PMID: 18386627 Review. Japanese.
-
Formation and development of Lewy pathology: a critical update.J Neurol. 2009 Aug;256 Suppl 3:270-9. doi: 10.1007/s00415-009-5243-y. J Neurol. 2009. PMID: 19711116 Review.
Cited by
-
Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia.PLoS One. 2020 Apr 22;15(4):e0231720. doi: 10.1371/journal.pone.0231720. eCollection 2020. PLoS One. 2020. PMID: 32320406 Free PMC article.
-
Liganded magnetic nanoparticles for magnetic resonance imaging of α-synuclein.NPJ Parkinsons Dis. 2025 Apr 23;11(1):88. doi: 10.1038/s41531-025-00918-z. NPJ Parkinsons Dis. 2025. PMID: 40268938 Free PMC article.
-
Neurodegeneration and the ordered assembly of α-synuclein.Cell Tissue Res. 2018 Jul;373(1):137-148. doi: 10.1007/s00441-017-2706-9. Epub 2017 Nov 8. Cell Tissue Res. 2018. PMID: 29119326 Free PMC article. Review.
-
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders.Clin Neurophysiol. 2011 Dec;122(12):2426-32. doi: 10.1016/j.clinph.2011.03.033. Epub 2011 May 26. Clin Neurophysiol. 2011. PMID: 21616709 Free PMC article.
-
The Synucleinopathies: Twenty Years On.J Parkinsons Dis. 2017;7(s1):S51-S69. doi: 10.3233/JPD-179005. J Parkinsons Dis. 2017. PMID: 28282814 Free PMC article. Review.
References
-
- Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging. 1997;18:S1–S2. - PubMed
-
- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456–462. - PubMed
-
- Adler CH. Nonmotor complications in Parkinson’s disease. Mov Disord. 2005;20 Suppl 11:S23–S29. - PubMed
-
- Beach TG, Tago H, Nagai T, Kimura H, McGeer PL, McGeer EG. Perfusion-Wxation of the human brain for immunohistochemistry: comparison with immersion-fixation. J Neurosci Methods. 1987;19:183–192. - PubMed